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  ABSTRACT 
  Objective      To develop evidence-based recommendations 
on how to investigate and follow-up undifferentiated 
peripheral inﬂ  ammatory arthritis (UPIA).   
  Methods      697 rheumatologists from 17 countries 
participated in the 3E (  E  vidence,   E  xpertise,   E  xchange) 
Initiative of 2008–9 consisting of three separate rounds of 
discussions and modiﬁ  ed Delphi votes. In the ﬁ  rst round 
10 clinical questions were selected. A bibliographic team 
systematically searched Medline, Embase, the Cochrane 
Library and ACR/EULAR 2007–2008 meeting abstracts. 
Relevant articles were reviewed for quality assessment, 
data extraction and synthesis. In the second round each 
country elaborated a set of national recommendations. 
Finally, multinational recommendations were formulated 
and agreement among the participants and the potential 
impact on their clinical practice was assessed.   
  Results      A total of 39 756 references were identiﬁ  ed, 
of which 250 were systematically reviewed. Ten 
multinational key recommendations about the 
investigation and follow-up of UPIA were formulated. 
One recommendation addressed differential diagnosis 
and investigations prior to establishing the operational 
diagnosis of UPIA, seven recommendations related to the 
diagnostic and prognostic value of clinical and laboratory 
assessments in established UPIA (history and physical 
examination, acute phase reactants, autoantibodies, 
radiographs, MRI and ultrasound, genetic markers and 
synovial biopsy), one recommendation highlighted 
predictors of persistence (chronicity) and the ﬁ  nal 
recommendation addressed monitoring of clinical disease 
activity in UPIA.   
  Conclusions      Ten recommendations on how to 
investigate and follow-up UPIA in the clinical setting were 
developed. They are evidence-based and supported by 
a large panel of rheumatologists, thus enhancing their 
validity  and  practical  use.      
  INTRODUCTION 
  In clinical practice, a large number of patients 
who present with recent-onset arthritis have 
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undifferentiated peripheral inﬂ  ammatory  arthri-
tis (UPIA). In this context, patients’ initial ques-
tions will focus on their likelihood of developing 
a well-deﬁ  ned rheumatic disease and on what the 
future holds for disease progression, persistence, 
functional impairment and quality of life. These 
are questions about future diagnosis and progno-
sis. The answers to these questions are vital for 
clinical decision making, including the choice of 
treatment. 
  The 3E Initiative (  E  vidence,   E  xpertise,   E  xchange) 
in rheumatology is a multinational effort aimed at 
promoting evidence-based medicine by formulat-
ing practical recommendations addressing clinical 
problems.    1        2    The objective of the 3E Initiative of 
2008–9 was to develop practical recommendations 
on how to investigate and follow-up undifferenti-
ated peripheral inﬂ  ammatory arthritis by integrat-
ing systematically generated evidence and expert 
opinion of a broad panel of international rheu-
matologists. Although the term ‘inﬂ  ammatory’ in 
UPIA may seem redundant, the reason for its use 
was to clearly distinguish the target population 
from patients with degenerative joint disease, often 
called osteoarthritis or degenerative arthritis in the 
English medical literature.   
  METHODS 
  A total of 697 rheumatologists from 17 countries 
participated in the 3E Initiative of 2008–9. Each 
country was represented by a scientiﬁ  c commit-
tee consisting of one principal investigator and 
5–13 members. The bibliographic team consisted 
of 10 international fellows (PM, IC, WK, RK, BK, 
MS, LS-F, KT, WV, EV) and ﬁ  ve mentors (DA, LC, 
RL, DvdH, CB), one of the mentors also being the 
scientiﬁ  c organiser (CB). The 17 national principal 
investigators were selected and invited by the 3E 
scientiﬁ   c organiser (CB) and each national chair 
was in charge of composing a national steering 
committee. The experts were all the members of 
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the 17 national steering committees who attended the multina-
tional meetings for the 3E Initiative. 
  During the ﬁ  rst international meeting (n=113 participants), 
10 clinically relevant questions on how to investigate and 
follow-up UPIA were formulated and selected via a modiﬁ  ed 
Delphi vote. The areas addressed were fourfold: (1) the phase 
prior to establishing the operational diagnosis of UPIA—namely, 
which differential diagnosis should be considered in a patient 
presenting with (inﬂ  ammatory) arthritis and the minimal inves-
tigations necessary to consider a patient as having UPIA; (2) 
the diagnostic and prognostic value of clinical assessment and 
investigations in UPIA (history and physical examination, acute 
phase reactants, autoantibodies, x-rays, MRI, ultrasound (US), 
genetic markers and synovial biopsy); (3) the predictors of per-
sistence (chronicity) in UPIA; and (4) the measures of clinical 
disease activity in UPIA. 
  The clinical questions were structured using the PIO format 
(Patients, Participants or Problem; Intervention or Index test; 
Outcomes or target conditions).    3    The patients included ‘adults 
with UPIA’. Duration of symptoms was not an exclusion cri-
terion. The deﬁ  nition of UPIA is controversial and there is no 
widely accepted classiﬁ  cation criterion for this condition. During 
the 2008–9 3E Initiative kick-off meeting, experts decided that 
only patients in whom clinically apparent joint swelling (syn-
ovial proliferation or synovial effusion) was observed by the 
rheumatologist should be included. For our review we sys-
tematically searched for studies of patients who did not fulﬁ  l 
diagnostic/classiﬁ  cation criteria for any speciﬁ  c rheumatic dis-
order after initial assessment. Studies with mixed populations 
(eg, UPIA+arthralgia, UPIA+early rheumatoid arthritis (RA)) 
were also retained, as these could be useful for extrapolating 
results. The intervention or index test was deﬁ  ned according 
to each question (eg, erosions on x-rays, anti-citrullinated pro-
tein/peptide antibodies (ACPA) positivity) and the index test 
should have been assessed at baseline. The outcomes were 
deﬁ  ned as the development of well-deﬁ  ned rheumatic diseases 
(eg, RA, psoriatic arthritis) or relevant disease outcomes (eg, 
remission, radiographic progression). As diagnostic/classiﬁ  ca-
tion criteria we accepted either internationally validated criteria 
(eg, American College of Rheumatology criteria for RA    4   ) or the 
opinion of the treating physician/investigator. 
  A systematic literature search for articles published up to 
February 2009 was carried out in Medline, Embase and Cochrane 
Library using comprehensive search strategies elaborated in col-
laboration with experienced librarians. The searches were lim-
ited to diagnostic and prognostic studies using a modiﬁ  cation 
of published sensitive search strategies.    5   –    8    No language restric-
tions were used. Retrieved citations were screened for titles, 
abstracts and full text using predeﬁ  ned inclusion and exclusion 
criteria; full read papers and review articles were hand-searched 
for additional references. Retained articles were graded for their 
methodological quality according to the levels of evidence of 
the Oxford Centre for Evidence-Based Medicine (http://www.
cebm.net/index.aspx?o=1025). 
  Each question was addressed separately by independent 
searches. For each question, relevant data were extracted and 
appropriate statistics were calculated, including OR, sensitiv-
ity, speciﬁ  city, positive/negative predictive values and positive/
negative likelihood ratios. Details and results of the literature 
search for each question will be published separately, while the 
current article describes the merging process between the evi-
dence found for each question and the interpretation of this by 
the experts, having the 10 recommendations as the result. 
  In the second round, a national meeting was held in each coun-
try (total=697 participants) to discuss the generated evidence and 
propose a set of recommendations. In a third joint meeting the 
17 scientiﬁ  c committees (n=94 participants) merged all proposi-
tions into 10 ﬁ  nal recommendations via discussion and modi-
ﬁ  ed Delphi vote. The grade of recommendation according to the 
Oxford levels of evidence was attributed and the level of agree-
ment was measured on a 10-point numerical rating scale (1=no 
agreement, 10=full agreement).    9    Finally, the potential effect of 
each recommendation in clinical practice was assessed accord-
ing to three impact statements voted by the rheumatologists.   
  RESULTS 
  A total of 39 756 references were identiﬁ  ed, of which 250 were 
systematically reviewed (  table 1  ). The 10 multinational key rec-
ommendations are listed in   table 2   with the corresponding level 
of evidence and grade of recommendation. The mean level of 
agreement among the rheumatologists was 8.7 (range 7.4–9.1). 
The percentage of rheumatologists who indicated they would 
change their clinical practice according to each recommendation 
is shown in   table 3  . Evidence for repeating investigations was 
not found for any of the questions, therefore all recommenda-
tions about this topic were based on expert opinion.       
  Recommendation 1.   All possible causes of arthritis (idiopathic, 
autoimmune, degenerative, infectious, malignancy, traumatic, metabolic) 
should be considered in the differential diagnosis. Complete history and 
thorough physical examination will determine the ranking order of pos-
sible differential diagnoses. Investigations should be based on the dif-
ferential diagnosis of the patient.   
  Table  1          Results of the systematic literature search for each recommendation topic   
  Recommendation (number and topic)    Retrieved references by 
systematic literature search (n) 
  Articles included in the 
systematic reviews (n) 
1. Pre-UPIA differential diagnosis and investigations 540 51
2. History and physical examination 2914 37
3. Acute phase reactants 3699 18
4. Autoantibodies 13217 64
5. X-rays 3585 25
6.1. MRI 2595 11
6.2. Ultrasound 2111 2
7. Genetic markers 3109 26
8. Synovial biopsy 6536 4
9. Predictors of persistence (chronicity) 437 7
10. Measures of clinical disease activity 1013 5
Total 39756 250
   UPIA,  undifferentiated  peripheral  inﬂ   ammatory  arthritis.   
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  As UPIA is an operational diagnosis after excluding well-
  deﬁ  ned rheumatic diseases, the question about pre-UPIA dif-
ferential diagnosis and investigations was analysed by looking 
at the diagnosis that was excluded in cohorts of patients with 
UPIA and by identifying the inclusion and exclusion criteria 
of these studies as well as the investigations performed before 
the UPIA cohort was established. RA was the most frequent 
diagnosis reported as exclusion criterion    10   –    59    and there was no 
standard baseline investigation undertaken prior to inclusion as 
UPIA (  table 4  ).    41   –    60      
  Experts agreed that, when facing a new patient presenting 
with arthritis, every diagnosis needed to be kept in mind as 
UPIA is an exclusion diagnosis. Although the consensus was that 
it was impossible to name all possible diagnoses, it was felt use-
ful to mention some major disease categories to make sure that 
these are considered. Experts also advised that UPIA should be 
constantly rethought, as patients may develop a disease that can 
be labelled with a speciﬁ  c diagnosis at any time. Moreover, this 
recommendation applies only if arthritis persists and not if it is 
self-limiting. Again, as the investigations will vary according to 
context and clinical presentation, experts felt that it would not be 
useful to make a list of recommended minimal investigations. 
  Recommendation 2.   To establish a speciﬁ  c diagnosis and prog-
nosis following presentation of UPIA, a careful systematic history and 
physical examination should be performed with particular attention to 
age, gender, geographical area, functional status, duration of symptoms/
early morning stiffness, number plus pattern of tender/swollen joints, 
axial/entheseal involvement and extra-articular/systemic features.   
  Although selected observational studies were of good qual-
ity, there was large heterogeneity with respect to the type of 
history and physical examination features described.    39        40        42   –    49    
    61   –    87    Of the quantiﬁ  ed features, advanced age,    44        83    female gen-
der    44    and greater morning stiffness    43        44    were predictive of an 
eventual diagnosis of RA. A higher number of tender    44    and 
swollen joints,    43        44        61    involvement of small joints of hands and 
feet,    44        83    involvement of both the upper and lower extremi-
ties    44    and symmetrical involvement    43    were also associated 
with progression to RA. Similar features were associated with 
disease persistence    81   –    87    and development of erosions,    48        63        78    
while self-reported functional disability (Health Assessment 
Questionnaire (HAQ) score)    67        76    and the presence of extra-
articular features    76    were uniquely predictive of future disabil-
ity, along with advanced age,    67        76    female gender    67    and longer 
symptom duration.    67    
  Table  2          Multinational recommendations on how to investigate and follow-up undifferentiated peripheral inﬂ  ammatory arthritis   
  Recommendation (with level of evidence and grade of recommendation)    Agreement mean (SD) 
1. All possible causes of arthritis (idiopathic, autoimmune, degenerative, infectious, malignancy, traumatic, metabolic) should be considered in the 
differential diagnosis. Complete history and thorough physical examination will determine the ranking order of possible differential diagnoses [5, D]. 
Investigations should be based on the differential diagnosis of the patient [5, D]
9.0 (1.7)
2. To establish a speciﬁ  c diagnosis and prognosis following presentation of UPIA, a careful systematic history and physical examination should be 
performed, with particular attention to age, gender [1a, A], geographical area [5, D], functional status [1a, A], duration of symptoms/early morning 
stiffness, number plus pattern of tender/swollen joints [1a, A], axial/entheseal involvement and extra-articular/systemic features [5, D]
8.8 (1.3)
3. ESR and CRP should be performed at baseline in the investigation for diagnosis [2b, B] and prognosis [2b, B] of UPIA and repeated when clinically 
relevant [5, D]
9.1 (1.4)
4. Testing of RF and/or ACPA should be performed in the evaluation of patients with UPIA, as these factors are predictive of RA diagnosis and prognosis; 
negative tests do not exclude progression to RA [1a, A]. If a connective tissue disease/systemic inﬂ  ammatory disorder is suspected, additional 
autoantibody tests should be considered [5, D]
9.1 (1.2)
5. X-rays of affected joints should be performed at baseline [5, D]. X-rays of hands, wrists and feet should be considered in the evaluation of UPIA as the 
presence of erosions is predictive for the development of RA and persistence of disease [1a, A]. These should be repeated within 1 year [5, D]
7.4 (2.6)
6. There is insufﬁ  cient evidence to recommend the routine use of MRI and US for diagnosis or prognosis in UPIA [5, D]; in UPIA and suspicion of RA, MRI 
of hands and wrists could be considered for diagnosis [2b, B]
8.2 (2.0)
7. There is no genetic test that can be routinely recommended [3b, D], however HLA-B27 testing may be helpful in speciﬁ  c clinical settings [5, D] 8.8 (1.5)
8. Routine synovial biopsy is not recommended but can give information for differential diagnosis, especially in patients with persistent monoarthritis 
[2b, B]
8.8 (1.8)
9. Predictors of persistent inﬂ  ammatory arthritis should be documented and include disease duration of ≥6 weeks [1b, A], morning stiffness >30 min 
[4, C], functional impairment [4, C], involvement of small joints [4, C] and/or knee [4, C], involvement of ≥3 joints [1b, B], ACPA [4, C] and/or RF positivity 
[4, C] and presence of radiographic erosion [1b, B]
8.6 (1.7)
10. Disease activity should be monitored [5, D], however no speciﬁ  c tool can be recommended [3b, C] 9.0 (1.7)
      Values in square brackets indicate [level of evidence, grade of recommendation] according to the Oxford Centre for Evidence-based Medicine levels of evidence. 
  Agreement was voted on a scale from 1 to 10 (fully disagree to fully agree) by the 94 rheumatologists attending the 3E Multi-National Closing Meeting. These attendees were members 
of the 17 scientiﬁ  c committees involved in the 3E Initiative of 2008–2009. 
  ACPA, anti-citrullinated protein/peptide antibodies; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; RA, rheumatoid arthritis; RF, rheumatoid factor; UPIA, undifferentiated 
peripheral inﬂ  ammatory arthritis; US, ultrasound.     
  Table  3          Percentage of rheumatologists in the 3E Initiative who indicated for each recommendation if it would change their clinical practice   
  Recommendation (number and topic)    The recommendation will 
change my practice (%) 
  The recommendation is 
already my practice (%) 
  I don’t want to change my 
practice for this aspect (%) 
1. Pre-UPIA differential diagnosis and investigations 0 96.5 3.5
2. History and physical examination 0 98.3 1.8
3. Acute phase reactants 5.4 91.1 3.6
4. Autoantibodies 1.8 96.4 1.8
5. X-rays 16.1 48.2 35.7
6. MRI and ultrasound 17.9 64.3 17.9
7. Genetic markers 1.8 92.9 5.4
8. Synovial biopsy 8.9 83.9 7.1
9. Predictors of persistence (chronicity) 24.6 66.7 8.8
10. Measures of clinical disease activity 12.3 84.2 3.5
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  Experts recognised the importance of the abovementioned 
evidence-based features and, based on their clinical experience, 
also highlighted the contribution of the patient’s geographical 
area of residence, the presence of axial/entheseal involvement 
and the presence of extra-articular/systemic features. However, 
the greater relevance given to features included in the recom-
mendation does not preclude the need to perform a careful sys-
tematic history and physical examination in every patient with 
UPIA. 
  Recommendation 3.   Erythrocyte sedimentation rate (ESR) and C 
reactive protein (CRP) should be performed at baseline in the investiga-
tion for diagnosis and prognosis of UPIA and repeated when clinically 
relevant.   
  Elevated erythrocyte sedimentation rate (ESR) showed 
some diagnostic value for the development of RA    74        85    but no 
prognostic value for persistence (chronicity) or structural dam-
age.    40        45        88    C reactive protein (CRP) appeared to be a poor 
predictor of persistent arthritis, radiological progression and 
functional disability.    80        89    However, there was some evidence 
for the usefulness of elevated CRP in predicting RA, espe-
cially when the CRP levels are higher.    48        88    In one study, CRP 
did not have any diagnostic value with regard to spondylar-
thropathy.    39    For other acute phase reactants, the evidence on 
diagnostic or prognostic value was scarce, negative or contro-
versial.    32        42        48        79        80        90   –    95    
  Based on sparse evidence and on personal experience regard-
ing acute phase reactants, experts recommended that only ESR 
and CRP should be performed at baseline and repeated accord-
ing to the clinical setting. 
  Recommendation 4.   Testing of rheumatoid factor (RF) and/or 
ACPA should be performed in the evaluation of patients with UPIA, as 
these factors are predictive of RA diagnosis and prognosis; negative tests 
do not exclude progression to RA. If a connective tissue disease/systemic 
inﬂ  ammatory disorder is suspected, additional autoantibody tests should 
be considered.   
  The association of ACPA and rheumatoid factor (RF)    11        42   –    44        48    
    50        73        96   –    110    with a diagnosis of RA at follow-up was compelling in 
the retrieved literature. The absence of ACPA or RF was diagnos-
tically less helpful. The presence of ACPA or RF    75        106   –    109        111   –    115    
also increased the probability of developing persistent synovitis 
or a worse radiographic outcome.    73        75        84   –    86        116    For anti-keratin 
antibodies (AKA) and anti-perinuclear factor, the evidence sug-
gests diagnostic usefulness; AKA also appears to have some 
prognostic value.    11        96   –    99        107        110        114        117    For all other markers includ-
ing a variety of other autoantibodies as well as bone and carti-
lage biomarkers, the evidence for diagnostic or prognostic value 
is scarce, negative or controversial.    57        102        118   –    126    The same applies 
to disease outcomes different from those already mentioned.    59    
    74        76        81        93        100        116        127        128    
  The value of ACPA and RF in UPIA was recognised and, based 
on clinical experience, experts also advised consideration of 
additional autoantibody tests if non-RA systemic inﬂ  ammatory 
disorders are suspected. The use of the general term ACPA was 
preferred as the literature describes several tests for detecting 
antibodies to citrullinated peptides (such as anti-CCP1 and anti-
CCP2) and newer generation tests are also expected to be used 
in the future. 
  Recommendation 5.   X-rays of affected joints should be performed 
at baseline. X-rays of hands, wrists and feet should be considered in 
the evaluation of UPIA as the presence of erosions is predictive for the 
development of RA and persistence of disease. These should be repeated 
within 1 year.   
  Radiographic erosions    43        49    and Larsen grade 1 (in a popula-
tion without erosions at baseline)    20    increased the probability 
of developing RA from UPIA. Moreover, when comparing mild 
versus progressive disease after 1 year follow-up, Sharp/van 
der Heijde scores at baseline were signiﬁ  cantly higher in the 
progressive disease group.    48    In another study,    44    erosions were 
found to be a predictor of RA in univariate but not in multivari-
ate analysis. 
  Overall, studies in mixed populations also provided some 
evidence for the usefulness of x-rays in predicting RA.    72        88    
    92        109        122        129   –    135    In general, prognosis was worse when radio-
graphic abnormalities at baseline were more severe.    75        91        109        116    
    133        136   –    140    
  Experts recognised the clinical value of hand and feet x-rays 
in UPIA and, based on clinical experience, also recommended 
that x-rays of affected joints should be performed at baseline; 
  Table  4           Diagnosis reported as exclusion criteria and baseline investigations undertaken prior to inclusion as UPIA (ordered by the frequency of 
reporting in the retrieved literature), both in studies including patients exclusively with UPIA as well as in selected mixed populations that included a 
well-deﬁ  ned subset of patients with UPIA   
A. Reported differential diagnosis prior to establishing the operational diagnosis of UPIA
- Rheumatoid arthritis
- Osteoarthritis
- Spondyloarthritis (reactive arthritis, psoriatic arthritis, ankylosing spondylitis and undifferentiated spondyloarthritis)
- Crystal-related arthritis
- Trauma
- Connective tissue diseases (systemic lupus erythematosus, Sjögren syndrome and myositis)
- Septic arthritis
- Sarcoidosis
- Soft tissue disorders
- Polymyalgia rheumatica
- Lyme disease
- Vasculitis
- Juvenile inﬂ  ammatory arthritis
- Palindromic rheumatism
- Fibromyalgia
- Endocrinological origin
- Malignancy-related arthritis
- Viral aetiology
B. Reported investigations prior to establishing the operational diagnosis of UPIA
- History
- Tender and swollen joint count
- Rheumatoid factor
- C reactive protein
- Physical examination
- Hands and feet x-rays
- Full blood count
- Antinuclear antibodies
- Erythrocyte sedimentation rate
- Biochemistry (liver function tests, glucose, urate and renal function)
- HLA typing (HLA-B27 and HLA-DR)
- Microbiological assessment
- Anti-citrullinated protein/peptide antibodies
- Radiography of the chest and/or of other affected joints
- Urinalysis
- Thyroid function tests
- C3, C4
- Immunoglobulins
- Antibodies to extractable nuclear antigens
- Antibodies to double-stranded DNA
- Speciﬁ  c serological assessment
   UPIA,  undifferentiated  peripheral  inﬂ   ammatory  arthritis.   
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furthermore, experts advised that x-rays should be repeated 
within 1 year (in case of disease persistence). Moreover, 
although not voted to be included in the recommendation, 
some of the experts expressed their opinion that pelvic/sac-
roiliac joint x-rays should also be considered, particularly 
in RF- and ACPA-negative patients or if spondyloarthritis is 
suspected. 
  There was a slightly lower agreement about this recommenda-
tion (  table 2  , 7.4 agreement), with a larger proportion of experts 
stating that they did not want to change their practice for this 
aspect (  table 3  , 35.7%). This lower concordance was mainly 
related to the inclusion of ‘x-rays of affected joints at baseline’ 
and about the advice to repeat x-rays ‘within 1 year’. 
  Recommendation 6.   There is insufﬁ  cient evidence to recommend 
the routine use of magnetic resonance imaging (MRI) and ultrasound 
(US) for diagnosis or prognosis in UPIA; in UPIA and suspicion of RA, 
MRI of hands and wrists could be considered for diagnosis.   
  Bone oedema was found to be an independent predictor of the 
future development of RA from UPIA,    141    and the presence of a 
distinct MRI synovitis and erosion pattern with the involvement 
of several hand joints but not the ﬁ  rst carpometacarpal joint also 
increased the probability of developing RA.    20    The absence of the 
same MRI synovitis pattern decreased the probability of devel-
oping RA.    20    Overall, MRI studies in mixed populations    101        134    
    142   –    147    provided some evidence for the usefulness of MRI (bone 
oedema, synovitis and erosions) in predicting RA. Regarding US, 
two mixed populations revealed US-power Doppler signal and 
US-gray scale synovitis as potential candidates for future studies 
in UPIA.    148        149    
  Experts recognised that MRI of the hands and wrists has 
already been shown to be useful in predicting the development 
of RA from UPIA, while the value of US in UPIA is still to be 
determined. However, data are still too scarce to recommend the 
routine use of any of these imaging tools. This recommendation 
does not dispute the fact that, compared with physical examina-
tion and x-rays, both MRI and US may offer advantages through 
more sensitive depiction of inﬂ  ammatory and destructive dis-
ease manifestations. The current recommendation pertains only 
to the diagnostic and prognostic value of these imaging tools in 
UPIA. 
  Recommendation 7.   There is no genetic test that can be routinely 
recommended, however HLA-B27 testing may be helpful in speciﬁ  c 
clinical settings.   
  There was a great heterogeneity among the genetic markers 
tested.    39        40        46        50   –    52        65        84        127        133        150   –    165    The shared epitope (SE) 
was the most frequently studied marker. Eight studies    40        50        65    
    133        153   –    155        158    tested its diagnostic utility and showed poor 
results. Only in one study was the positive likelihood ratio 
for RA relevant, but this result came from the study with the 
poorest quality and smallest sample size.    40    In isolation, no 
other genetic marker was informative of a future diagnosis 
in patients with UPIA. With regard to prognosis, the SE was 
weakly associated with a poor prognosis of arthritis in terms 
of development of erosions, mortality, disability and persistent 
synovitis.    65        127        133        163        164    Other genes were not good predictors 
of erosions or other less studied outcomes. 
  The experts acknowledged the current lack of evidence for 
the practical utility of genetics in UPIA. However, based on 
their clinical experience, experts chose to highlight that HLA-
B27 may be helpful in the appropriate clinical setting—namely, 
when spondyloarthritis is suspected. 
  Recommendation 8.   Routine synovial biopsy is not recommended 
but can give information for differential diagnosis, especially in patients 
with persistent monoarthritis.   
  Studies had signiﬁ   cant clinical and statistical hetero-
geneity.    22        23        166        167    Three broad synovial features of interest 
were identiﬁ  ed in the literature: ACPA staining, immunohisto-
chemistry and vascular patterns. In contrast to serological ACPA 
testing, ACPA staining was shown not to be highly speciﬁ  c 
for a diagnosis of RA.    167    In one study, synovial histopathology 
seemed to differentiate between RA and non-RA.    166    The vascu-
lar pattern in undifferentiated arthritis was not speciﬁ  c enough 
to differentiate between spondyloarthritis and RA.    22        23    
  The exact role of synovial biopsy in UPIA is yet to be deter-
mined and experts felt that it could not be recommended as a 
routine procedure. However, experts also highlighted the fact 
that synovial biopsy may give important diagnostic clues, espe-
cially in some selected cases (eg, persistent/chronic refractory 
monarthritis, suspicion of malignancy or suspicion of chronic 
infection such as tuberculosis). 
  Recommendation 9.   Predictors of persistent inﬂ  ammatory arthritis 
should be documented and include disease duration of ≥6 weeks, morn-
ing stiffness >30 min, functional impairment, involvement of small joints 
and/or knee, involvement of ≥3 joints, ACPA and/or RF positivity and 
presence of radiographic erosion.   
  The question about chronicity was investigated by looking 
at prognostic studies that used multivariate analysis to identify 
independent predictors of persistence (chronicity). At baseline 
the following variables were found to be independent predictors 
of persistent (inﬂ  ammatory) arthritis: disease duration,    75        82        116    
duration of morning stiffness,    75        85        86    change of functional status 
(measured by HAQ) in the ﬁ  rst 3 months,    82    failure to respond 2 
weeks after local treatment with intra-articular corticosteroids,    82    
small joint involvement,    168    knee involvement,    85    presence of 
RF,    75        85    presence and level of ACPA,    75        86        168    functional status 
(HAQ),    169    arthritis of at least three joints,    75    proximal interpha-
langeal joint involvement,    169    metatarsophalangeal joint involve-
ment    75    and radiographic erosion at the hands and feet.    75    The 
magnitude of the association in the same predictor was diverse 
among the studies depending on the patient characteristics 
(namely, if the population was purely UPIA or not), the study 
design and the variables used to adjust for in the models. 
  Recommendation 10.   Disease activity should be monitored, how-
ever no speciﬁ  c tool can be recommended.   
  Five studies evaluated the validation of different clinical mea-
sures in patients with UPIA. Validation aspects of four ques-
tionnaires (WHO Disability Assessment Schedule,    170    London 
Handicap Scale, Disease Repercussion Proﬁ  le and the HAQ    171   ) 
and three physical measures (RA Disease Activity Index,    172    
McGill Range of Motion Index    173    and NOAR Damage Joint 
Count    174   ) were partially assessed in these studies but none of 
the instruments of disease activity was fully validated for its use 
in UPIA. 
  Although no instrument of disease activity has been fully vali-
dated for its use in UPIA, experts felt that it was important to 
recommend that there should be a conscious effort to record 
disease activity.   
  DISCUSSION 
  Ten multinational recommendations on how to investigate and 
follow-up UPIA in the clinical setting were developed, which 
are practical, evidence-based and supported by a large panel of 
international rheumatologists in the 3E Initiative. 
  We followed an established group decision method. A repre-
sentative expert panel of 697 academic and community rheu-
matologists from 17 countries selected relevant questions that 
reﬂ  ect the challenges of approaching a patient with UPIA. They 
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openly discussed the evidence from the literature followed by a 
silent voting process. We used the touch pad methodology with 
prespeciﬁ  ed cut-off levels of agreement to generate the ﬁ  nal rec-
ommendations. Several rounds of rewording and revoting were 
sometimes required to reach the speciﬁ  ed cut-off for agreement. 
This process highlights the international dimension of this col-
laboration and strengthens the current recommendations.    1        2    It 
ensured that the ﬁ  nal recommendations were evidence-driven 
as well as clinically relevant. 
  Furthermore, the broad participation increases external valid-
ity and enhances future dissemination and implementation into 
rheumatological practice worldwide. Another main feature of 
the 3E Initiative was the promotion of epidemiology and sys-
tematic literature research, all participants having been updated 
on how to appraise published evidence. 
  There is widespread interest in predictive medicine. Following 
a strict methodology, we aimed to ﬁ  nd all available evidence 
regarding each question which resulted in a large number of 
reviewed articles. However, the evidence in truly UPIA popula-
tions is scarce, exposing the need to create a research agenda 
addressing this topic. In particular, future studies should clearly 
distinguish between individuals with early well-deﬁ  ned rheu-
matic diseases, individuals with UPIA and individuals with 
inﬂ  ammatory joint symptoms but no obvious joint swelling. All 
these populations can be studied for predictive algorithms and 
results may be different depending on the study population. 
  The deﬁ  nition of UPIA is controversial and much of the litera-
ture is skewed towards early RA. The difﬁ  culty in deﬁ  ning UPIA 
is underlined by the continuous changing face of different cat-
egories of patients, which can be well illustrated by the recent 
new ACR/EULAR criteria for RA,    175    as several of the patients 
we now describe as having UPIA will likely be labelled as having 
RA. Nevertheless, despite the inﬂ  uence that this changing may 
have on research and daily practice, the recommendations pre-
sented in this article are based on currently available evidence. 
They may help the clinician in the effective management of 
patients with UPIA and can be adjusted if future studies or clini-
cal experience reveal new insights. 
  In summary, multinational recommendations for the investi-
gation and follow-up of patients with undifferentiated arthritis 
in daily clinical practice were developed, integrating systematic 
literature review and expert opinion with the aim of promot-
ing evidence-based medicine and ultimately improving patient 
care.     
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